FDA Approves Winrevair, Merck’s Novel Treatment for Pulmonary Arterial Hypertension

Winrevair is the first FDA-approved activin signaling inhibitor therapy for pulmonary arterial hypertension.

Source link
#FDA #Approves #Winrevair #Mercks #Treatment #Pulmonary #Arterial #Hypertension